Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03

Treatments are limited after platinum Cetuximab or anti-PD1 failure for patients with recurrent/metastatic head and neck squamous cell carcinoma. Cabazitaxel has increased overall survival in hormone-refractory metastatic prostate cancer after failure of Docetaxel. Our aim was to detect a signal of...

Descripción completa

Detalles Bibliográficos
Autores principales: Fayette, Jerome, Guigay, Joel, Tourneau, Christophe Le, Degardin, Marian, Peyrade, Frederic, Neidhardt, Eve-Marie, Sablin, Marie-Paule, Even, Caroline, Orlandini, Florence, Juzyna, Béata, Bellera, Carine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584293/
https://www.ncbi.nlm.nih.gov/pubmed/28881692
http://dx.doi.org/10.18632/oncotarget.15901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584293/
https://www.ncbi.nlm.nih.gov/pubmed/28881692
http://dx.doi.org/10.18632/oncotarget.15901

Ejemplares similares